![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Pfizer Settles Charges Over Its Copayment Card Program
Pfizer Settles Charges Over Its Copayment Card Program
October 19, 2018
Pfizer has settled allegations that it falsely marketed its copayment coupon program for its Estring, Quillivant and Flector Patch products.
The drugmaker will pay $500,000 in penalties, fees and costs to the State of New York and more than $200,000 in consumer restitution, according to New York Attorney General Barbara Underwood.
Pfizer distributed the copayment coupons — which displayed in large, obvious text that eligible customers would “PAY NO MORE THAN” a certain out-of-pocket amount — to consumers throughout New York “without clearly and conspicuously disclosing” the terms and conditions, Underwood said.
Upcoming Events
-
21Oct